Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors that has shown better glycemic control and greater weight loss compared to selective GLP-1RAs in patients with type 2 diabetes [59]
Pruritus was reported in 4%, 2%, and 2% of patients (including adolescents) receiving topiramate 50 mg/day, 100 mg/day, and 200 mg/day, respectively, for migraines in placebo-controlled (2%) clinical trials
doi: 10.1007/s00018-016-2133-1 131 NikiMJyotakiMYoshidaRYasumatsuKShigemuraNDiPatrizioNVet al
"Packaging Innovations for Maintaining Stability of Sensitive Pharmaceutical Compounds." International Journal of Pharmaceutics, 614, 121418.
2021;5: e594
Until robust Phase 3 trial results are available, injectables and oral formulations remain the evidence-based standard for GLP-1 therapy initiation